Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of dapagliflozin on exercise capacity and hemodynamics in pulmonary arterial hypertension
2021-006787-25Phase 2Active
- Sponsor
- The Heart Centre, Rigshospitalet
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Dapagliflozin (Forxiga) arm with Placebo arm (2 arms). Primary endpoint: Maximum oxygen consumption (VO2 max). Started Dec 2021; status: active.
02
Drugs
dapagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2021-006787-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006787-25.